Geode Capital Management LLC Has $8.39 Million Stock Holdings in CeriBell, Inc. $CBLL

Geode Capital Management LLC boosted its position in CeriBell, Inc. (NASDAQ:CBLL) by 55.4% during the second quarter, HoldingsChannel.com reports. The fund owned 447,936 shares of the company’s stock after buying an additional 159,698 shares during the quarter. Geode Capital Management LLC’s holdings in CeriBell were worth $8,391,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CBLL. Quantbot Technologies LP bought a new position in shares of CeriBell in the 1st quarter valued at $175,000. Rhumbline Advisers lifted its position in shares of CeriBell by 26.5% during the 1st quarter. Rhumbline Advisers now owns 15,629 shares of the company’s stock worth $300,000 after buying an additional 3,276 shares during the last quarter. Nuveen LLC acquired a new stake in CeriBell in the first quarter valued at about $311,000. Swiss National Bank bought a new position in CeriBell in the first quarter valued at about $467,000. Finally, Emerald Mutual Fund Advisers Trust raised its stake in CeriBell by 26.1% during the second quarter. Emerald Mutual Fund Advisers Trust now owns 98,185 shares of the company’s stock worth $1,839,000 after acquiring an additional 20,350 shares in the last quarter.

CeriBell Stock Up 6.4%

Shares of NASDAQ CBLL opened at $19.15 on Friday. The company has a 50 day simple moving average of $13.27 and a 200 day simple moving average of $14.40. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. CeriBell, Inc. has a 1 year low of $10.01 and a 1 year high of $32.75. The firm has a market cap of $710.47 million, a PE ratio of -12.68 and a beta of 1.35.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. The firm had revenue of $22.59 million for the quarter, compared to analyst estimates of $21.78 million. On average, research analysts forecast that CeriBell, Inc. will post -2.46 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Xingjuan Chao sold 25,000 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $16.59, for a total transaction of $414,750.00. Following the completion of the transaction, the chief executive officer directly owned 798,135 shares of the company’s stock, valued at $13,241,059.65. This trade represents a 3.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CTO Raymond Woo sold 11,112 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $12.28, for a total value of $136,455.36. Following the completion of the sale, the chief technology officer owned 167,704 shares in the company, valued at $2,059,405.12. This trade represents a 6.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 109,163 shares of company stock valued at $1,597,291 over the last 90 days. 20.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CBLL. JPMorgan Chase & Co. reduced their price target on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. TD Cowen cut their target price on shares of CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research note on Wednesday, October 8th. Finally, Raymond James Financial assumed coverage on CeriBell in a research note on Tuesday, October 21st. They issued a “strong-buy” rating and a $19.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, CeriBell currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.17.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.